Evidence map›Paper›PMID 38445816›Full record

ReviewJournal of mass spectrometry : JMS2024

Spatial neurolipidomics-MALDI mass spectrometry imaging of lipids in brain pathologies.

Durga Jha, Kaj Blennow, Henrik Zetterberg, Jeffrey N Savas, Jörg Hanrieder

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of mass spectrometry : JMS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. ExploringFrontiers in cell and developmental biology · 2026
    Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

Durga JhaDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal Hospital, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal Hospital, Mölndal, Sweden.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal Hospital, Mölndal, Sweden.
Jeffrey N SavasDepartment of Neurology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
Jörg HanriederDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Mölndal Hospital, Mölndal, Sweden.ORCID https://orcid.org/0000-0001-6059-198X
Northwestern University · USSahlgrenska University Hospital · SEUniversity of Gothenburg · SEUniversity of Science and Technology of China · CNUniversity of Wisconsin–Madison · US

Funding

Understanding Amyloid Pathology - Multiomic Activity Imaging of Plaque Formation Dynamics (AmyMAP)R01AG078796 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Jeffrey Nicholas Savas · 2022 to 2026
$2.7M
Long-lived proteins as pillars of mitochondrial architecture in rodent brainsR21AG072343 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SAVAS, JEFFREY NICHOLAS · 2022 to 2023
$440k
Human in vivo stable isotope labeling kinetics (iSILK) to quantify brain amyloid plaque kineticsR21AG078538 · NIA · WASHINGTON UNIVERSITY · PI HANRIEDER, JORG, SCHWETYE, KATHERINE · 2022 to 2022
$411k
Insights into Amyloid Pathogenicity DynamicsR21AG080705 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI HANRIEDER, JORG, SAVAS, JEFFREY NICHOLAS · 2023 to 2024
$401k
Alzheimer's Association SG-23-1038904 QCAlzheimer's Association ZEN-21-848495NIA NIH HHS R01 AG078796NIA NIH HHS R21 AG072343NIA NIH HHS R21 AG078538NIA NIH HHS R21 AG080705NIH HHS R01 AG078796NIH HHS R21AG072343NIH HHS R21AG078538NIH HHS R21AG080705
6 · The paper itself

Abstract

Given the complexity of nervous tissues, understanding neurochemical pathophysiology puts high demands on bioanalytical techniques with respect to specificity and sensitivity. Mass spectrometry imaging (MSI) has evolved to become an important, biochemical imaging technology for spatial biology in biological and translational research. The technique facilitates comprehensive, sensitive elucidation of the spatial distribution patterns of drugs, lipids, peptides, and small proteins in situ. Matrix-assisted laser desorption ionization (MALDI)-based MSI is the dominating modality due to its broad applicability and fair compromise of selectivity, sensitivity price, throughput, and ease of use. This is particularly relevant for the analysis of spatial lipid patterns, where no other comparable spatial profiling tools are available. Understanding spatial lipid biology in nervous tissue is therefore a key and emerging application area of MSI research. The aim of this review is to give a concise guide through the MSI workflow for lipid imaging in central nervous system (CNS) tissues and essential parameters to consider while developing and optimizing MSI assays. Further, this review provides a broad overview of key developments and applications of MALDI MSI-based spatial neurolipidomics to map lipid dynamics in neuronal structures, ultimately contributing to a better understanding of neurodegenerative disease pathology.

Indexed as

Neurodegenerative DiseasesBrainHumansLipidsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationWorkflowLipidsAlzheimer's disease (AD)amyloidgangliosidesinositolslysolipidsmass spectrometry imaging (MSI)matrix-assisted laser desorption ionization (MALDI)neurolipidomicsNiemann-Pick disease type C1 (NPC1)Parkinson's disease (PD)spatial biologysphingolipids

Identifiers

PMID38445816
PMCPMC12013527
OpenAlexW4392507819

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.